Memorial Sloan Kettering Cancer Center
Trial to assess hydroxychloroquine for COVID-19 prevention during cancer treatment
A randomized phase 2 clinical trial will assess hydroxychloroquine for prevention of COVID-19 infection among patients undergoing radiation therapy for cancer.
Children with cancer ‘at no higher risk’ for COVID-19 infection, morbidity
Children and adolescents with cancer do not appear at higher risk for infection or morbidity from COVID-19 compared with their cancer-free counterparts, according to single-center findings published as a research letter in JAMA Oncology.
Watch-and-wait strategy may be appropriate for certain patients with rectal cancer
A nonoperative watch-and-wait strategy appeared comparable to upfront surgery in survival outcomes and could confer a quality-of-life benefit and significant cost savings for certain patients with rectal cancer, according to results of a modeling study published in Journal of the National Cancer Institute.
Parker Institute for Cancer Immunotherapy awards grants to six early career researchers
Memorial Sloan Kettering Cancer Center announces appointments
Memorial Sloan Kettering Cancer Center announced several appointments.
Targeted therapy shows promise for HER2-mutant NSCLC, other solid tumors
The novel HER2-targeted antibody-drug conjugate fam-trastuzumab deruxtecan-nxki appeared active in a cohort of patients with various heavily pretreated HER2-expressing or HER2-mutant solid tumors, according to results of a dose-expansion study published in Cancer Discovery.
Anti-PD-1 therapy induces durable long-term responses in advanced melanoma
About three-quarters of patients with advanced melanoma who achieved complete responses to single-agent anti-PD-1 therapy remained in remission at 3 years, according to results of a single-center retrospective study published in Journal of Clinical Oncology.
Enfortumab vedotin plus pembrolizumab induces durable responses in metastatic urothelial carcinoma
The combination of enfortumab vedotin and pembrolizumab conferred high rates of durable responses among cisplatin-ineligible patients with metastatic urothelial carcinoma, according to results of the multicohort EV-103 study.
Targeted conditioning improves transplant rate for relapsed, refractory AML
ORLANDO — Targeted conditioning with anti-CD45 iodine apamistamab enabled older, heavily pretreated patients with relapsed or refractory acute myeloid leukemia to undergo hematopoietic stem cell transplantation with successful engraftment, according to preliminary results of the randomized phase 3 SIERRA trial presented at TCT | Transplantation & Cellular Therapy Meetings.
Link between gut microbiota, clinical outcomes generalizable among allogeneic HSCT recipients
Patterns of microbiota disruption, marked by loss of intestinal diversity and single taxa domination, appeared similar among a cohort of patients undergoing allogeneic hematopoietic stem cell transplantation across various centers and geographic areas, according to findings published in The New England Journal of Medicine.